CN1281603C - 作为抗炎药的氨基吡咯化合物 - Google Patents

作为抗炎药的氨基吡咯化合物 Download PDF

Info

Publication number
CN1281603C
CN1281603C CNB028166310A CN02816631A CN1281603C CN 1281603 C CN1281603 C CN 1281603C CN B028166310 A CNB028166310 A CN B028166310A CN 02816631 A CN02816631 A CN 02816631A CN 1281603 C CN1281603 C CN 1281603C
Authority
CN
China
Prior art keywords
compound
phenyl
alkyl
compounds
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028166310A
Other languages
English (en)
Chinese (zh)
Other versions
CN1547578A (zh
Inventor
D·M·戈尔德施泰因
D·M·罗特施泰因
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1547578A publication Critical patent/CN1547578A/zh
Application granted granted Critical
Publication of CN1281603C publication Critical patent/CN1281603C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB028166310A 2001-08-30 2002-08-26 作为抗炎药的氨基吡咯化合物 Expired - Fee Related CN1281603C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31616901P 2001-08-30 2001-08-30
US60/316,169 2001-08-30

Publications (2)

Publication Number Publication Date
CN1547578A CN1547578A (zh) 2004-11-17
CN1281603C true CN1281603C (zh) 2006-10-25

Family

ID=23227809

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028166310A Expired - Fee Related CN1281603C (zh) 2001-08-30 2002-08-26 作为抗炎药的氨基吡咯化合物

Country Status (16)

Country Link
US (1) US6696471B2 (cg-RX-API-DMAC7.html)
EP (1) EP1423378B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005506324A (cg-RX-API-DMAC7.html)
KR (1) KR20040029075A (cg-RX-API-DMAC7.html)
CN (1) CN1281603C (cg-RX-API-DMAC7.html)
AR (1) AR037140A1 (cg-RX-API-DMAC7.html)
AT (1) ATE309239T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002331179B2 (cg-RX-API-DMAC7.html)
BR (1) BR0212077A (cg-RX-API-DMAC7.html)
CA (1) CA2458808A1 (cg-RX-API-DMAC7.html)
DE (1) DE60207273T2 (cg-RX-API-DMAC7.html)
ES (1) ES2252509T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA04001810A (cg-RX-API-DMAC7.html)
PL (1) PL373115A1 (cg-RX-API-DMAC7.html)
RU (1) RU2315045C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003020715A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60331367D1 (de) 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
WO2006020365A2 (en) * 2004-07-26 2006-02-23 The Regents Of The University Of California Method for prevention or treatment of inflamatory disease
EP2131858A4 (en) * 2007-03-20 2011-11-23 Cadila Pharmaceuticals Ltd P38 INHIBITORS
US20180325947A1 (en) 2015-10-27 2018-11-15 Children's Hospital Medical Center Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and/or genetic manipulation
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068234A (en) * 1990-02-26 1991-11-26 Sterling Drug Inc. 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles
EP0912548A1 (en) 1996-07-11 1999-05-06 Pfizer Inc. Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
EP0956018A4 (en) * 1996-08-21 2000-01-12 Smithkline Beecham Corp IMIDAZOLE COMPOUNDS, COMPOSITIONS CONTAINING THEM AND THEIR USE
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
PL344004A1 (en) 1998-05-05 2001-09-10 Hoffmann La Roche Pyrazole derivatives as p-38 map kinase inhibitors
AU3859999A (en) * 1998-05-14 1999-11-29 G.D. Searle & Co. 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors

Also Published As

Publication number Publication date
PL373115A1 (en) 2005-08-08
KR20040029075A (ko) 2004-04-03
EP1423378B1 (en) 2005-11-09
US20030130319A1 (en) 2003-07-10
RU2315045C2 (ru) 2008-01-20
AR037140A1 (es) 2004-10-27
EP1423378A1 (en) 2004-06-02
ATE309239T1 (de) 2005-11-15
MXPA04001810A (es) 2004-07-08
RU2004109817A (ru) 2005-10-20
US6696471B2 (en) 2004-02-24
DE60207273D1 (de) 2005-12-15
BR0212077A (pt) 2004-09-28
WO2003020715A1 (en) 2003-03-13
ES2252509T3 (es) 2006-05-16
JP2005506324A (ja) 2005-03-03
CA2458808A1 (en) 2003-03-13
AU2002331179B2 (en) 2008-04-17
CN1547578A (zh) 2004-11-17
DE60207273T2 (de) 2006-07-20

Similar Documents

Publication Publication Date Title
CN1157378C (zh) 喹啉衍生物
CN101952256B (zh) 1-苄基-3-羟基甲基吲唑衍生物及其在治疗基于MCP-1、CX3CR1和p40表达的疾病中的用途
CN1849310A (zh) 作为大麻素受体调制剂的噻唑衍生物
CN1639164A (zh) 含氮杂环化合物
CN1041203C (zh) 吡唑并吡啶化合物的制备方法
CN1100773C (zh) 苯并呋喃羧酸胺和磺酰胺
CN1726191A (zh) 用作纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代的吲哚氧代－乙酰氨基乙酸衍生物
CN101061107A (zh) 肉桂酰胺化合物的无定形物
CN88102247A (zh) 新颖的吡唑并[3，4-d]嘧啶、其制备方法及其药物组合物
CN1068566A (zh) 用作抗缺血剂的2-(4-羟基哌啶子基)-1-烷醇
CN1051551C (zh) 新型吡咯并咔唑衍生物
CN1261887A (zh) 氮杂环丁基丙基哌啶衍生物、中间体以及作为速激肽拮抗剂的用途
CN1305465A (zh) 芳基链烷酰基哒嗪化合物
CN1281603C (zh) 作为抗炎药的氨基吡咯化合物
CN1142227A (zh) 新的噻唑烷-4-酮衍生物
CN1269811C (zh) 具有sst1拮抗活性的哌嗪衍生物
CN1956978A (zh) 作为肥大细胞类胰蛋白酶抑制剂的[4－(5－氨基甲基－2－氟－苯基) －哌啶－1－基] －(4－溴－3－甲基－5－丙氧基－噻吩－2－基)-甲酮盐酸盐
CN1795176A (zh) 作为毒蕈碱受体拮抗剂的氮杂双环衍生物
CN101039671A (zh) 非肽类缓激肽拮抗剂及其药物组合物
CN1299357A (zh) 主要用于治疗骨质疏松的吲哚衍生物
CN1774250A (zh) 作为治疗诸如类风湿性关节炎的炎性疾病的p38激酶抑制剂的(6－(苯氧基)－吡啶并[3,4－d]嘧啶－2－基)－胺衍生物
AU2002331179A1 (en) Aminopyrrole compounds as antiinflammatory agents
NO171847B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzenderivater
CN1289333A (zh) 用作血清素－1a受体激动剂的噁唑衍生物
CN1058397A (zh) 1-二苯甲基哌嗪的新颖衍生物，其制备方法及其医药用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20061025

Termination date: 20090928